Opioid dose, duration, and risk of use disorder in Medicaid patients with musculoskeletal pain
Pain Medicine · 01.01.2026 · 27 (1) · 4-14
DOI: 10.1093/pm/pnaf077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pain Medicine, online erschienen am 24.06.2025. Verfasst von Allison Perry und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Health, NYU Grossman School of Medicine, New York, NY 10016, United States. Hauptthemen laut MEDLINE: Analgesics, Opioid, Musculoskeletal Pain, Opioid-Related Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, College on Problems of Drug Dependence and Board of Directors, Interdisciplinary Association of Population Health Sciences, President of the Interdisciplinary Association of Population Health Sciences.
Abstract (Originalsprache)
Importance The CDC recommends initiating opioids for pain treatment at the lowest effective dose and duration; however, how dose, duration, and drug type jointly influence opioid use disorder risk remains a critical gap not addressed by current guidelines.
Objective
We examine how interactions between dose, duration, and other medication factors (eg, drug type) influence opioid use disorder (OUD) risk. Design, Setting, Participants, Interventions Using Medicaid claims data (2016-2019) from 25 states, we analyzed opioid-naïve adults, newly diagnosed with musculoskeletal pain who initiated opioids within 3 months of diagnosis. A 6-month washout confirmed no prior opioid exposure or musculoskeletal diagnosis. Initial opioids were categorized by “dose-days supplied” (low [>0-20 mg MME] to very high [>90 mg MME] dose, and short [1-7 days] to moderate [>7-30 days] supply) and by opioid type; physical therapy (PT) sessions were also recorded. Using Poisson regression models, we estimated the OUD risk associated with dose-days categories, adjusting for baseline demographics, clinical characteristics, and medications. We separately examined opioid dose-days and PT, and assessed PT’s moderating effect on dose-days’ impact.
Results
Among 30 536 patients, half initiated opioids at 20-50 MME for 1-7 days, and 20% received PT. OUD risk was 2-3 times higher for opioids initiated for >7-30 days compared to 1-7 days across doses, and 5.5 times higher for opioids initiated for >7-30 days at >90 MME versus 1-7 days at <20 MME. PT alone, neither affected OUD risk nor mitigated the increased risk from longer or higher dose opioids.
Conclusions
Our findings support the need for careful opioid prescribing and alternative pain management strategies, as the observed associations between initial prescription characteristics and OUD were not mitigated by adjunctive PT. Relevance This study demonstrated that initial opioid prescriptions of 7-30 days, especially above 90 MME/day, increased OUD risk in opioid-naïve patients with musculoskeletal pain; physical therapy did not mitigate the risk. Different opioids posed varied risks, even at the same dose and duration. Careful prescribing and alternative pain management are essential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Population Health, NYU Grossman School of Medicine, New York, NY 10016, United States.
- Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ 08901, United States.
- Department of Health Behavior, Society and Policy, Rutgers School of Public Health, Piscataway, NJ 08854, United States.
- Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, United States.
ORCID-Profile: Allison Perry, Noa Krawczyk, Kara E Rudolph
Förderung
- NIDA NIH HHS
- College on Problems of Drug Dependence and Board of Directors, Interdisciplinary Association of Population Health Sciences
- President of the Interdisciplinary Association of Population Health Sciences
- National Institute on Drug Abuse
- NIDA
Zitieren
APA
Perry, A., Krawczyk, N., Samples, H., Martins, S. S., Hoffman, K., Williams, N. T., Hung, A., Ross, R., Doan, L., Rudolph, K. E., & Cerdá, M. (2026). Opioid dose, duration, and risk of use disorder in Medicaid patients with musculoskeletal pain. Pain Medicine, 27(1), 4-14. https://doi.org/10.1093/pm/pnaf077
Vancouver
Perry A, Krawczyk N, Samples H, Martins SS, Hoffman K, Williams NT, et al. Opioid dose, duration, and risk of use disorder in Medicaid patients with musculoskeletal pain. Pain Medicine. 2026;27(1):4-14. doi:10.1093/pm/pnaf077
BibTeX
@article{Perry2026,
author = {Perry, Allison and Krawczyk, Noa and Samples, Hillary and Martins, Silvia S and Hoffman, Katherine and Williams, Nicholas T and Hung, Anton and Ross, Rachael and Doan, Lisa and Rudolph, Kara E and Cerdá, Magdalena},
title = {Opioid dose, duration, and risk of use disorder in Medicaid patients with musculoskeletal pain},
journal = {Pain Medicine},
year = {2026},
volume = {27},
number = {1},
pages = {4--14},
doi = {10.1093/pm/pnaf077}
}
EUVIMED